Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

Dermatol Ther. 2020 Nov;33(6):e14258. doi: 10.1111/dth.14258. Epub 2020 Sep 11.

Authors

Valdemar Wendelboe Nielsen¹, Tamara Theresia Lund¹, Robert Gniadecki², Rasmus Huan Olsen^{1

3}, Christoffer Valdemar Nissen¹, Jakob Ferløv Baselius Schwensen¹, Simon Francis Thomsen^{1

4}

Affiliations

¹ Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
² Division of Dermatology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
³ Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark.
⁴ Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

PMID: 32865289
DOI: 10.1111/dth.14258

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / adverse effects
Biosimilar Pharmaceuticals / adverse effects
Humans
Infliximab
Psoriasis* / diagnosis
Psoriasis* / drug therapy

Substances

Biosimilar Pharmaceuticals
Infliximab
Adalimumab